Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
The VZN and ZEN studies are non-comparative trials assessing triple combination therapy comprising thymidine and non-thymidine analogue nucleoside reverse transcriptase inhibitors plus a protease inhibitor. Preliminary data are available for the VZN study and recruitment for the ZEN study is underway.
Anderson
R D
RD
Anderson Clinical Research, Inc., Pittsburgh, PA 15213, USA.
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir; D016049:Didanosine